{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biological%2FVaccine&page=2", "query": { "intervention": "Biological/Vaccine", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 1338, "total_pages": 134, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biological%2FVaccine&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Biological%2FVaccine&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-03T23:18:41.813Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00923195", "title": "Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma", "Skin Cancer" ], "interventions": [ { "name": "MART-1: 26-35(27L) Peptide", "type": "DRUG" }, { "name": "Montanide ISA 51 VG", "type": "DRUG" }, { "name": "gp100:154-162 Peptide", "type": "DRUG" }, { "name": "Radiation", "type": "PROCEDURE" }, { "name": "Aldesleukin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Anti-gp 100:154 TCR PBL", "type": "GENETIC" }, { "name": "Anti-MART-1 F5 TCR PBL", "type": "GENETIC" } ], "intervention_types": [ "DRUG", "PROCEDURE", "GENETIC" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2008-12", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2015-10-28", "last_synced_at": "2026-10-03T23:18:41.813Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00923195" }, { "nct_id": "NCT02213354", "title": "H7N9 Mix and Match With MF59 in Healthy Elderly Persons", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Avian Influenza" ], "interventions": [ { "name": "MF59", "type": "DRUG" }, { "name": "Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "65 Years to 99 Years" }, "enrollment_count": 479, "start_date": "2014-10", "completion_date": "2016-07", "has_results": false, "last_update_posted_date": "2017-07-06", "last_synced_at": "2026-10-03T23:18:41.813Z", "location_count": 10, "location_summary": "Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 7 more", "locations": [ { "city": "Decatur", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02213354" }, { "nct_id": "NCT06060457", "title": "A Study to Evaluate the Safety and Immune Response of mRNA-1345, a Vaccine Targeting Respiratory Syncytial Virus (RSV), When Co-administered With a Fluzone HD, in Adults ≥65 Years of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Respiratory Syncytial Virus" ], "interventions": [ { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "mRNA-1345", "type": "BIOLOGICAL" }, { "name": "Fluzone HD", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ModernaTX, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "65 Years", "maximum_age": null, "sex": "ALL", "summary": "65 Years and older" }, "enrollment_count": 1900, "start_date": "2023-09-25", "completion_date": "2024-06-07", "has_results": true, "last_update_posted_date": "2025-07-30", "last_synced_at": "2026-10-03T23:18:41.813Z", "location_count": 34, "location_summary": "Scottsdale, Arizona • Dublin, California • Riverside, California + 29 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Dublin", "state": "California" }, { "city": "Riverside", "state": "California" }, { "city": "Rolling Hills Estates", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06060457" }, { "nct_id": "NCT02126579", "title": "Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Metastatic Melanoma", "Mucosal Melanoma" ], "interventions": [ { "name": "Peptide Vaccine (LPV7) + Tetanus peptide", "type": "BIOLOGICAL" }, { "name": "PolyICLC", "type": "OTHER" }, { "name": "Resiquimod", "type": "OTHER" }, { "name": "IFA", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Craig L Slingluff, Jr", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2014-05-01", "completion_date": "2021-05-05", "has_results": true, "last_update_posted_date": "2024-02-28", "last_synced_at": "2026-10-03T23:18:41.813Z", "location_count": 2, "location_summary": "Houston, Texas • Charlottesville, Virginia", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02126579" }, { "nct_id": "NCT01310413", "title": "Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Influenza", "Influenza Vaccines" ], "interventions": [ { "name": "Influenza A (H5N1) Virus monovalent vaccine", "type": "BIOLOGICAL" }, { "name": "Saline placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "6 Months", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Months to 17 Years" }, "enrollment_count": 842, "start_date": "2011-03-07", "completion_date": "2014-01-26", "has_results": true, "last_update_posted_date": "2021-11-01", "last_synced_at": "2026-10-03T23:18:41.813Z", "location_count": 11, "location_summary": "Paramount, California • Sacramento, California • Newton, Kansas + 8 more", "locations": [ { "city": "Paramount", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Newton", "state": "Kansas" }, { "city": "Bardstown", "state": "Kentucky" }, { "city": "Metairie", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT01310413" }, { "nct_id": "NCT04886154", "title": "A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Infections, Meningococcal" ], "interventions": [ { "name": "MenABCWY-2Gen low dose vaccine", "type": "COMBINATION_PRODUCT" }, { "name": "MenABCWY-2Gen high dose vaccine", "type": "COMBINATION_PRODUCT" }, { "name": "Placebo", "type": "COMBINATION_PRODUCT" }, { "name": "MenB vaccine", "type": "COMBINATION_PRODUCT" }, { "name": "MenACWY vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "COMBINATION_PRODUCT", "BIOLOGICAL" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "10 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "10 Years to 50 Years" }, "enrollment_count": 1440, "start_date": "2021-06-14", "completion_date": "2024-02-02", "has_results": true, "last_update_posted_date": "2025-05-31", "last_synced_at": "2026-10-03T23:18:41.813Z", "location_count": 12, "location_summary": "Colorado Springs, Colorado • Longmont, Colorado • Doral, Florida + 9 more", "locations": [ { "city": "Colorado Springs", "state": "Colorado" }, { "city": "Longmont", "state": "Colorado" }, { "city": "Doral", "state": "Florida" }, { "city": "Miami Lakes", "state": "Florida" }, { "city": "Meridian", "state": "Idaho" } ], "official_url": "https://clinicaltrials.gov/study/NCT04886154" }, { "nct_id": "NCT00666380", "title": "A Study to Determine the Effects of an Investigational Malaria Vaccine Given to Adults Living in the United States and Thereafter to Adults Living in Kenya", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Malaria" ], "interventions": [ { "name": "Plasmodium falciparum Malaria Protein 010 (FMP010)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "U.S. Army Medical Research and Development Command", "sponsor_class": "FED", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 26, "start_date": "2008-04", "completion_date": "2009-06", "has_results": false, "last_update_posted_date": "2015-05-29", "last_synced_at": "2026-10-03T23:18:41.813Z", "location_count": 1, "location_summary": "Silver Spring, Maryland", "locations": [ { "city": "Silver Spring", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00666380" }, { "nct_id": "NCT04745559", "title": "Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large-Cell Lymphoma", "Primary Mediastinal Large B-Cell Lymphoma (PMBCL)", "Transformed Follicular Lymphoma (TFL)", "High-grade B-cell Lymphoma (HGBCL)", "Follicular Lymphoma" ], "interventions": [ { "name": "Pneumococcal conjugate vaccine (PCV13)", "type": "BIOLOGICAL" }, { "name": "CD19 targeted CAR T Cell Therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2021-02-18", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-10-03T23:18:41.813Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04745559" }, { "nct_id": "NCT00295958", "title": "LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)", "Non-melanomatous Skin Cancer" ], "interventions": [ { "name": "LMB-2 immunotoxin", "type": "BIOLOGICAL" }, { "name": "MART-1 antigen", "type": "BIOLOGICAL" }, { "name": "gp100 antigen", "type": "BIOLOGICAL" }, { "name": "incomplete Freund's adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2005-12", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2012-06-14", "last_synced_at": "2026-10-03T23:18:41.813Z", "location_count": 2, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00295958" }, { "nct_id": "NCT05031078", "title": "Assessing Durable Antibody Response to HPV Vaccination", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HPV" ], "interventions": [ { "name": "Gardasil-9", "type": "BIOLOGICAL" }, { "name": "Lidocaine injections", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 17, "start_date": "2021-12-21", "completion_date": "2026-03-26", "has_results": true, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-10-03T23:18:41.813Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05031078" } ] }